Memory loss isn’t normal. Could your memory loss be more than aging?

A clinical research study for those with symptoms of early Alzheimer’s disease. If you or a loved one are experiencing problems with memory or challenges performing complex tasks, you may qualify for a clinical research study for those with symptoms of early Alzheimer’s disease.

Welcome to the PROSPECT-ALZ Study, where we’re exploring a potential treatment to delay or slow the progression of Alzheimer’s.

We’re looking for men and women ages 60-85 who have shown a gradual decline in their memory function over the last 6 months or more to help us evaluate an investigational medicine to see if it might potentially delay or slow memory decline.

About Early Symptomatic Alzheimer’s Disease

Early symptomatic Alzheimer’s disease causes a small but noticeable and measurable decline in cognitive skills. It involves problems with memory and thinking ability, behavior, and mood.

If you have early symptomatic Alzheimer’s disease, you may be noticing changes in your memory. You may feel like your mental functions are “slipping,” but the changes have not become severe enough to significantly interrupt your daily life.

  • Alzheimer’s disease, a type of dementia, may begin 20 years or more before symptoms arise.
  • Someone with early symptomatic Alzheimer’s disease is at an increased risk of developing Alzheimer’s dementia or another dementia.
  • Approximately 15% to 20 % of people aged 65 or older have mild cognitive impairment (MCI), an indicator of early symptomatic Alzheimer’s disease.
  • Among those with MCI, about 1/3 (32%) develop Alzheimer’s dementia within 5 years.
  • The risk factors most strongly linked to Alzheimer’s disease are advancing age, family history of Alzheimer’s or another dementia, and conditions that raise risk for cardiovascular disease.


The PROSPECT-ALZ Clinical Research Study is researching the safety and effectiveness of an investigational medicine that targets the tau protein, a substance in the brain that supports brain neuron structure and helps nutrients travel to different parts of a cell.

For people with Alzheimer’s disease, tau proteins in the brain break down inside neurons and stick to each other, forming tangles that cause neurons to die and block communication from one part of the brain to another. This study will research whether the investigational medicine can slow or prevent these tangles from forming. Scientists think that this may help to delay or slow memory loss in people with early stages of Alzheimer’s disease.

The study involves people who have memory loss that has gotten worse over the last 6 months or more. If you are experiencing memory loss or struggling to perform complex tasks, you may prequalify.

If you qualify, participation can range from 1 year and 6 months to 2 years and 8 months, with up to 31 appointments with the study center.

Who can participate in the PROSPECT-ALZ Clinical Research Study?

The PROSPECT-ALZ Study is looking for participants to research an investigational medicine for those who have experienced memory loss due to early stages of Alzheimer’s disease. In order to meet study entry requirements, the participant must:

  • Be 60 to 85 years old
  • Have memory loss that has gotten worse over time
  • Have a reliable study partner* who knows you and is willing to go to appointments with you or be available by phone at certain times throughout the study

*The study partner must be able to speak about the participant’s daily routines and any changes with the research staff throughout the study.

There are additional criteria that are reviewed by the study team at the study center at the first appointment.

The study coordinator can answer any more questions you may have about the PROSPECT-ALZ Study. For more information about memory loss, we encourage you to speak with your doctor.

If prequalified, what can I expect on my first visit to the study center?

This initial appointment is an opportunity for you to:

Learn more about the PROSPECT-ALZ Clinical Research Study. You’ll be speaking with a study coordinator at the study center to learn more regarding your participation in this study.

Ask any important questions you may have. These can be any questions you may have about this study or clinical research in general.

Determine if the PROSPECT-ALZ Clinical Research Study may be right for you. The study coordinator will ask you about your health history to determine if you are eligible for the study. If you are eligible, you will be given the opportunity to decide if participation is right for you. If you agree to take part, you will be asked to review and sign a consent form for study participation. Once you have signed the study consent form, the research staff will perform a series of tests to determine if you are right for the study, and if the study is right for you.

How long is this study?

If you qualify, participation can range from 1 year and 6 months to 2 years and 8 months, with up to 31 appointments with the study center. The study coordinator can answer any questions you have about the PROSPECT-ALZ Study.

Will I have to discontinue any current medicine?

Do not discontinue any medicine unless you are advised to do so by the study center staff or your primary care physician.

Does participating in this study cost me anything?

There is no cost to you or your insurance provider for participating in this study. If you qualify for this study, study-related care may be provided at no cost to you.

For U.S. participants: Do I need health insurance to participate?

No, health insurance is not required in order to participate.

Are thinking and memory problems adding to your challenge of dealing with Parkinson’s disease or Lewy body disorder? If so, participating in our clinical research study of an investigational drug for people with mild cognitive impairment may be a good option for you or a loved one.

We understand that living with Parkinson’s disease or Lewy body disorder is a daily challenge. In addition to the physical difficulties of the disease, problems with thinking and memory are often present. These thinking and memory problems, called mild cognitive impairment, affect 15% to 25% of newly diagnosed Parkinson’s patients. This impairment has been associated with increased disability and can negatively affect quality of life.
People with mild cognitive impairment associated with Parkinson’s disease (MCI-PD) are six times more likely to develop dementia. It is very important to us to conduct clinical research studies with the goal of finding additional treatment options. This is the reason we are conducting this clinical research study. If you have mild cognitive impairment associated with Parkinson’s disease or related Lewy body disorder, or are close with someone who does, please read these answers to commonly asked questions about this study.
What is being researched in this study?
This study seeks to evaluate the safety, tolerability, and effect of a drug called NYX-458 (the “investigational drug”) in people who have mild cognitive impairment or mild dementia associated with  Parkinson’s disease or dementia with Lewy bodies. We are also conducting research into whether it can help with thinking and memory problems.
Who can participate in this study?
To qualify for this study, potential study participants must meet the following criteria:
  • Be 50 to 85 years of age with Parkinson’s disease or a related Lewy body disorder
  • Have a study partner* willing to assist during the study
  • Have symptoms of mild cognitive impairment, such as:
    • difficulties with problem solving or paying attention
    •  slowed thinking
    •  issues with short-term memory
*The study partner is someone who has frequent contact with the study participant and is willing and able to provide information about the participant and attend some study visits.
There are additional requirements to participate. The staff at the study center will explain the complete list of requirements.
What will happen during this study?
At the first visit, the study doctor’s staff will give a detailed explanation of this study and its potential risks and benefits. This explanation will be made verbally and in writing. Only after obtaining written consent from the potential participant will study-specific procedures take place. The study partner must also attend this first visit and give written consent to participate.
Next, the study doctor and the doctor’s staff will conduct a series of study-related examinations and tests to see if the participant satisfies the requirements to enroll in this study. The study staff will schedule a second screening visit for those participants who satisfy the initial screening requirements. The second screening visit will be at least one week after the first and further tests will be conducted. These two visits comprise the total screening period for participation in this study, and this screening period will last between 14 and 28 days.
Participants who remain qualified after the second visit will be asked to return to begin the treatment period of the study. Qualified study participants will then be randomly assigned into either a placebo group or a dosing group of the study drug. A placebo is a substance that looks like the study drug but has no active ingredients. Neither participants nor study personnel will know which assignment has been made.
Study participants will take the study drug or placebo once daily for 12 weeks. During these 12 weeks, there will be 4 visits to the study center and 3 phone calls with the study doctor’s staff. At these visits, study personnel will continue to examine participants and perform various cognitive and safety assessments. Approximately two weeks after the last dose, participants will return for a final
follow-up visit.
At all in-person visits during the treatment period, the study staff will ask the participant’s designated study partner to answer questions related to the participant’s cognitive function. The study partner must attend the first visit of the treatment period to answer these cognitive questions but may answer these questions by telephone if unable to attend subsequent visits.
This study will involve approximately 100 participants.
How long will the study last?
Complete participation in this study will last between 16 and 18 weeks. It will involve seven visits to the study doctor’s office and three scheduled phone calls with the study doctor’s staff.
Does it cost anything to participate?
There is no cost to participate. Qualified participants receive the investigational drug or placebo and required study-related medical assessments and examinations at no cost. Compensation for time and travel expenses incurred as a result of study participation may also be available.
Are there any risks to participating in this study?
There may be potential risks to participating in this study. All drugs and medical procedures carry a risk of side effects; therefore, it is possible that participants may experience some discomfort or other reactions from use of the study drug. If you decide to participate, the study staff will explain the potential risks to you before any study procedures are conducted.
What are the potential benefits of participating?
Participants may or may not receive any benefit from being in this study. It is possible that participants may get better, stay the same, or get worse. In the future, other people with mild cognitive impairment or mild dementia associated with Parkinson’s disease or prodromal or manifest Lewy body dementia may be helped by this research.
What are the next steps?
If you or your loved one wish to take the next step toward possible participation or if you have more questions, please contact us as directed on the back of this brochure. Contacting us does not obligate you to participate in this study.

This website is for informational purposes only. Please dial 911 for emergency.

Lewy Body Dementia Study
This is default text for notification bar